Non-Histaminic Angioedemaema
Non-histaminic angioedema: A syndrome characterized by intermittent and repeated episodes of subcutaneous and/or submucosal swelling causing apparent edema and/or abdominal pain. Unlike allergic reactions, this kind of angioedema is not induced by histamine, so its treatment pathway is very different. Protheragen is focused on innovative diagnostics and therapies that quickly solve and assist your research requirements for Non-Histaminic Angioedema.
Introduction to Non-Histaminic Angioedemaema
Non-histaminic angioedema can be of two kinds: Hereditary Angioedema (HAE) and Acquired Angioedema (AAE). HAE usually starts during childhood or teenage years, and it arises from genetic errors in the C1 inhibitor, which produces high levels of bradykinin. On the contrary, AAE is typically experienced post-50 and is often related to other conditions such as lymphoproliferative diseases or anti-C1-INH autoantibodies. Both types are characterized by non-itchy swelling that lasts 48 to 72 hours and may affect the gastrointestinal tract and be more dangerous if the throat is affected.
Fig. 1 Bodily locations of HAE attacks. (Broderick L, et al., 2025)
Our Services
At Protheragen, we specialize in cutting-edge drug discovery, offering comprehensive preclinical development services for non-histamine angioedema. Our team has a strong grasp of cutting-edge technology and processes to ensure rapid drug development, and our solutions are tailored to address the special issues that come with non-histamine angioedema research.
By Molecule Type
By Research Phase
Our Non-Histaminic Angioedema Model Development Services
At Protheragen, we have expertise in the creation of Non-Histaminic Angioedema models to capture the depth and complexities of non-histaminic angioedema as a therapeutic dynamic that is an essential part of rare disease research. These models help us assess the safety and efficacy of novel therapies and therefore can speed up the pipeline.
In Vitro Models
Our in vitro models enable detailed exploration of cellular behaviors and drug efficacy in non-histaminic angioedema, aiding in the identification of potential therapeutic targets and understanding disease mechanisms.
- 3D Bioprinting Models
- Organ-on-a-Chip Models
- Spheroids
- Microfluidic Cell Culture
- Organoid Models
In Vivo Models
Our in vivo models provide a holistic view of non-histaminic angioedema, supporting the evaluation of treatment strategies and offering insights into disease progression and systemic therapeutic responses.
- Genetically Engineering Model
- Induced Disease Model
- Humanized Animal Model
- Syngeneic Model
- Xenograft Model
With extensive expertise in rare disease R&D services, our company offers comprehensive support, ensuring swift responses to evolving research needs. We provide professional communication and assistance, from disease model development to innovative therapy research. For more details and quotation information, please contact us .
Reference
- Broderick L, et al. The adolescent experience of hereditary angioedema: a qualitative study of disease burden and treatment experience. Orphanet J Rare Dis. 2025 Jan 10;20(1):16.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.